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The pannexin (Panx) family of proteins, which is co-expressedwith connexins (Cxs) in vertebrates, was found to
be a new GJ-forming protein family related to invertebrate innexins. During the past ten years, different studies
showed that Panxs mainly form hemichannels in the plasma membrane and mediate paracrine signalling by
providing a flux pathway for ions such as Ca2+, for ATP and perhaps for other compounds, in response to
physiological andpathological stimuli. Although thephysiological role of Panxs asahemichannelwas questioned,
there is increasing evidence that Panx play a role in vasodilatation, initiation of inflammatory responses, ischemic
deathof neurons, epilepsyand in tumor suppression.Moreover, it is intriguing that Panxsmay also function at the
endoplasmic reticulum (ER) as intracellular Ca2+-leak channel and may be involved in ER-related functions.
Although the physiological significance and meaning of such Panx-regulated intracellular Ca2+ leak requires
further exploration, this functional property places Panx at the centre of many physiological and
pathophysiological processes, given the fundamental role of intracellular Ca2+ homeostasis and dynamics in a
plethora of physiological processes. In this review, we thereforewant to focus on Panx as channels at the plasma
membrane and at the ER membranes with a particular emphasis on the potential implications of the latter in
intracellular Ca2+ signalling.
© 2010 Elsevier Inc. All rights reserved.
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1. Introduction
Cells often respond towards extracellular stimuli, like hormones,
growth factors, amino acids and purinergic signalling molecules by the
generation of an intracellular Ca2+ signal [1]. In many cases,
extracellular activation generates intracellular signalling molecules,
like inositol 1,4,5-trisphosphate (IP3) [2]. Elevating intracellular IP3
levels leads to intracellular Ca2+ release that originates from the
endoplasmic reticulum (ER) by the opening of IP3-gated channels
(IP3Rs) [3]. The unique spatiotemporal properties of the Ca2+ signal
controls a variety of downstream cellular and physiological processes,
including gene transcription, cell proliferation, cell survival/death,
hormone secretion, enzyme release, actin cytoskeletal contraction,
neurotransmitter release and according to synaptic plasticity [2].
In many cases, the cells neither function stochastically nor
independently from each other, but rather display a coordinated
response towards signalling molecules. This coordination is of utmost
importance for the physiological outcome of these processes at the
tissue or whole-organ level [4,5], and results from intercellular
communication and signalling. The most direct way is via the head-
to-head docking of hexameric connexin-based gap junctional channels,
allowing the passage of small signalling molecules with a molecular
weight of less than 1.5 kDa [6–8]. The activity of these gap junctional
channels is tightly regulated by intra- and intermolecular protein
interactions and a variety of cellular signalling events, including redox
modification and phosphorylation [9]. These gap junctions dictate the
coordinated response of connected cells, which can be seen as a
chemical and electrical syncitium. The latter is very clear in the heart,
where the spreading of an action potential across the atrial and
ventricular myocytes is based on connexin-based gap junctional
channels [10]. In addition to establishing direct cellular connections,
connexins have been shown to act as unapposed “hemichannels” that
participate in the release of signalling molecules, like ATP in purinergic
signalling [11,12]. Besides connexins, a new family of gap junctional-
related channels has been identified, the pannexins (Panx) [12–15].
These channels primarily act as ATP-permeable hemichannels rather
than gap junctions [16]. Recent findings also indicated the location of
Panx in the ER, thereby forming Ca2+-permeable channels [17,18].
Hence, given their potential role at the plasma membrane and the ER,
Panx channels may be at the centre of many signalling processes.
Wewill first present a general overviewof the differentmechanisms
that control intracellular Ca2+ homeostasis. In the next paragraphs we
describe the role of Panx channels at the plasma membrane as critical
mediators of physiological andpathophysiological signalling. Finally,we
discuss the possible role of Panx channels in the ERwith an emphasis on
their potential role as Ca2+-leak channels and function in neurogenesis.
2. Intracellular Ca2+ signals: an overview
In cells ranging from bacteria to highly differentiated eukaryotic
cells, ionized calcium (Ca2+) is universal and physiologically important
intracellular signalling molecule. In all eukaryotic cells, the cytoplasmic
concentration of Ca2+ ([Ca2+]i) is tightly controlled by complex
interplay between Ca2+-pumps, Ca2+-channels, Ca2+-exchangers and
Ca2+-binding proteins [19]. Global or local changes in [Ca2+]i modulate
a wide range of intracellular functions. Muscle contraction, secretion,
metabolism, neuronal excitability, cell differentiation, cell proliferation
and cell death all depend on Ca2+ [20]. The large number of diseases
caused by mutations and abnormalities in various proteins involved in
the cellular Ca2+ regulation also emphasize the importance of Ca2+ as
an intracellular messenger [21].
The cytoplasmic basal Ca2+ activity is maintained at about 100 nM,
which ismuch lower than the extracellular Ca2+concentration ([Ca2+]o),
which is in the mM range (Fig. 1). Many stimuli can trigger the
activation of phospholipase C β/γ (PLC β/γ) and the generation of IP3,
resulting in the release of Ca2+ from internal Ca2+ stores and a
subsequent increase in the cytoplasmic [Ca2+]. The increase in [Ca2+]i
dependson thepresence anddensity of cytosolic Ca2+-bufferingproteins
or Ca2+-buffering organelles such as mitochondria. Furthermore,
specialized Ca2+ microdomains arise in the close proximity of multi-
protein complexes involving Ca2+-channels, which affect local
signalling processes or the activity of other proteins, like enzymes
and channels [19]. These localized microdomains are established
through the formation of Ca2+ channel multi-protein complexes,
thereby recruiting a variety of effector proteins. Ca2+ is delivered
from both extracellular space and internal Ca2+ stores, such as
endoplasmic and sarcoplasmic reticulum (ER and SR), nuclear
envelope or Golgi apparatus (Fig. 1). The [Ca2+] in these stores is at
least 1000-fold higher than the basal cytoplasmic [Ca2+], creating a
high driving force for Ca2+ release from the intracellular stores. High
Table 1
Cellular functions of Panx channel.
Functions at the plasma membrane
Taste bud receptors Panx1 mediates ATP release to control gustatory afferent nerves during tastant-evoked signalling
Neurons Panx mediates chemical coupling
Red blood cells Panx1 mediates ATP release to control microcirculation and micro-environment of the vasculature
Skeletal muscle cells Panx1 mediates ATP release linked to excitation–transcription regulation during tetanic contractions
Airway epithelial cells Panx1 mediates ATP release to control mucociliary clearance and maintain proper airway epithelial function during stress
Chondrocytes Panx1 mediates ATP release (and concomitant decline in intracellular cAMP levels) to control differentiation and proliferation
Keratinocytes Panx1 causes disorganization, whereas Panx3 channels mediate differentiation
T cells/B cells Panx1 mediates ATP as co-stimulator for antigenic stimulation
Cells of immune system Panx1 in “death pore”-complex formation with P2X7
Functions at the ER or other intracellular compartments
Prostate cancer cells Panx1 as ER Ca2+-leak channel
Glioma Panx2 as an inhibitor of cell growth/proliferation
Neuronal progenitor cells Panx2 neurogenesis and stem-cell like behavior
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cytoplasmic [Ca2+] levels and long-lasting Ca2+ increases are toxic
[22,23] and may lead to apoptosis and necrosis [24–26]. Therefore,
intracellular Ca2+ levels are accurately regulated inmagnitude, space
and time by the intrinsically low permeability of the plasma
membrane to ions, and by the activity of channels, pump mechan-
isms and exchangers in the plasmamembrane and in themembranes
of the intracellular Ca2+ stores [19]. Cells possess an extensive ‘Ca2+
signalling toolkit’ in order to fulfill their physiological functions. Each
cell type has a pallet of Ca2+-ON mechanisms, regulating [Ca2+]i
increase, and Ca2+-OFF mechanisms, used to decrease the [Ca2+]i
after Ca2+ has carried out its signalling functions [2]. By employing
the different components of this pool of Ca2+-handling proteins, cells
are able to alter the amplitude, speed, space, and time duration of the
Ca2+ signal [2]. These mechanisms lead to Ca2+ transients that
originate in a restricted area of the cell and spread throughout the
whole cell as an intracellular Ca2+ wave.
Release of Ca2+ from intracellular stores occurs in most situations
secondary to activation of PLC. Upon PLC activation, IP3 is formed from
phosphatidyl 4,5-bisphosphate (PIP2) and binds to the cytosolic face
of the IP3 receptor (IP3R), inducing receptor activation, channel
opening and the release of Ca2+ from ER Ca2+ stores [27]. Another
intracellular Ca2+-release channel is the ryanodine receptor (RyR),
which is physiologically activated by direct interaction with the
dihydropyridine receptor (RyR1 in skeletal muscle) or by Ca2+ influx
through L-type Ca2+ channels (RyR2 in cardiac muscle) (Fig. 1) [28].
Importantly, RyRs also participate in IP3R-mediated Ca2+ signalling
via a mechanism known as Ca2+-induced Ca2+ release (CICR). Other
physiological activators of RyRs include adenosine-based second
messengers, like cyclic adenosine diphosphate ribose (cADPr) [29].
Nicotinic acid adenine dinucleotide phosphate (NAADP) is involved in
the production of a Ca2+ signal via the recently described family of
two-pore channels (TPC) [30–32]. This Ca2+ signal can be amplified
by CICR by recruiting other intracellular Ca2+-release mechanisms
[33]. Finally, polycystin-2 has been proposed to operate as a Ca2+-
release channel in the ER [34]. The activation mechanism of
polycystin-2 is not fully understood but involves Ca2+-induced Ca2+
release via a recently identified EF-hand Ca2+-binding site in
polycystin-2 [35] and the complex formation with IP3R [36,37] and
RyRs [38].
Besides the presence of intracellular Ca2+-release channels in
the ER, which open in response to signalling molecules, like IP3 and/or
Ca2+, one of the most enigmatic processes that control ER Ca2+
dynamics is the passive Ca2+ leak from the ER. Nevertheless, the
molecular nature of the passive Ca2+-leak channel has not yet been
fully identified and understood. Many molecular candidates (pre-
senilins [39], polycystin-2 [40–42], translocon [43,44], but see also
[45], Bax Inhibitor-1 [46], hypersensitive IP3Rs activatable by basal IP3
levels [47,48], caspase-3-cleaved IP3Rs [49–51] and ER-localized
Panx1 channels [18]), have been proposed to account for the passive
Ca2+-leak channel, but as yet there is no consensus about the
mechanism or function of either of them. On the one hand, the effects
of many of these proteins on ER Ca2+ or their Ca2+-channel properties
were often reported by only one single group or could not be
confirmed by other laboratories. On the other hand, in many cases,
these proteins interact with the IP3R and RyR Ca2+-release channels,
and may thereby affect their Ca2+-flux properties [36–38,52–54]. It
remains therefore difficult to allocate the effects of the candidate
proteins on [Ca2+]ER as originating from their own Ca2+ permeability
rather than from an indirect effect on existing ER Ca2+-release
channels.
Activation of Ca2+ signalling is rapidly terminated and resting
conditions for [Ca2+]i are restored, by rapid removal of Ca2+ from the
cytosol. This termination of the Ca2+ signal occurs via Ca2+ extrusion
mechanisms, such as the plasma membrane Ca2+–ATPase (PMCA) and
the Na+/Ca2+ exchanger (NCX), and mechanisms refilling the intracel-
lular stores, like sarco-endoplasmic reticulum Ca2+ ATPases (SERCAs)
(Fig. 1). In addition to the role of Ca2+-buffering proteins, mitochondria
modulate agonist-induced Ca2+ signals due to the physical association
of the ER withmitochondria, known as the mitochondria-associated ER
membrane (MAM), allowing highly efficient transmission of Ca2+ from
Fig. 1. Ca2+-signalling pathways. Schematic representation of the main players in Ca2+ homeostasis and of the different Ca2+-release mechanisms.
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the ER to mitochondria [55,56]. Given the high local [Ca2+] in the ER/
mitochondrialmicrodomains (between 5 and 20 μM), even low-affinity
mitochondrial Ca2+-uptakemechanisms can rapidly promote Ca2+ flux
down its electrochemical gradient. The membrane potential over the
inner mitochondrial membrane is highly negative (−180 mV) and is
established by the translocation of protons across the inner mitochon-
drial membrane via respiratory chain complexes (Fig. 1).
In the absence of compensatory Ca2+-influx mechanisms, the ER
Ca2+ store content would empty over time, leading to ER stress and
cell death. Therefore, proper ER Ca2+-store content must be
adequately maintained by store-operated Ca2+-influx mechanisms
[57]. Recent studies identified Stim proteins as the ER luminal sensor
that activates store-operated Ca2+ channels, like the newly discov-
ered Orai channels [58–64]. Upon Ca2+-store depletion, Stim
oligomerizes and translocates to punctae that are in close proximity
with discrete plasma membrane patches, in which plasmalemmal
Orai Ca2+ channels are recruited by direct or indirect association with
Stim1 and become activated, leading to Ca2+ influx (Orai, for review
[57,65]) (Fig. 1). Besides the role of STIM1/Orai proteins in store-
operated Ca2+ entry, these proteins have been proposed to be integral
parts of the highly Ca2+-selective ARC channels, which are activated
by arachidonic acid [66]. ARC channels, whose pentameric architec-
ture is composed of Orai1/Orai3 subunits, are not regulated by store
depletion, but require a pool of STIM1 that is constitutively present in
the plasma membrane. Other mechanisms that can mediate [Ca2+]i
increases through Ca2+ influx involve the opening of plasma
membrane Ca2+ channels, which are divided into three different
classes according to their activation mechanism, the voltage operated
Ca2+ channels (VOCs), which open following a decrease of membrane
potential [67], the second messenger operated channels (SMOCs),
which open in response to the binding of a second messenger on the
inner surface of the membrane [68] and the receptor operated Ca2+
channels (ROCs), also called ligand-gated channels, which open
following the binding of an external ligand (Fig. 1) [69].
Besides these plasmalemmal channels, it has become increasingly
clear that Pannexins (Panx) can form non-selective large-pore
hemichannels in the plasma membrane [70]. Since Panx channels
might permeate Ca2+ ions and can release signalling molecules that
lead to intracellular Ca2+ release, it is likely that Panx channels
modulate intracellular Ca2+ homeostasis. Panxs have a broad
expression in the central nervous system (CNS) [71,72]. Panx
channels are known to release signalling molecules, like ATP and
arachidonic acid derivatives, from neurons and possibly astrocytes
[8,73]. In isolated taste cells, Panx1 hemichannels are shown to
release ATP and mediate cell–cell communication [74]. This may
contribute to novel forms of non-synaptic communication in the CNS,
thereby affecting synaptic function, astrocytic Ca2+ wave propagation
and possibly regulation of vascular tone in the brain. In vitro
experiments have suggested a possible role for Panx1 channels in
ischemic, excitotoxic and ATP-dependent cell death, whereas Panx
coupling with purinergic receptors triggers the inflammasome
(reviewed in [75]). In this review, we will focus on Panx channels as
release channels in the plasma membrane and we will in addition
discuss their possible role as Ca2+-leak channels in the ER.
3. Expression, function and localization of Panx channels
In contrast to the 24 members that have been identified in the
Cx-protein family (identified by their molecular mass), the Panx
family contains only three members (Panx1, Panx2 and Panx3)
[14,76]. The Panx-protein family is highly conserved from the worm
to mammals [14]. Although Panx channels do not share sequence
homology with Cx channels, they display a similar overall structure
and permeability properties. Panx channels consist of an N-terminal
cytosolic domain, 4 transmembrane domains (TMD) with two
extracellular loops between TMD1/TMD2, and TMD3/TMD4, an
intracellular loop between TMD2/TMD3, and a C-terminal cytosolic
domain [14,17,77]. Multimeric Panx proteins are known to predom-
inantly form large-pore channels in the plasma membrane [13,78].
Different cellular processes, including membrane depolarization and
intracellular Ca2+ signals, are known to activate and open Panx
channels [12]. These channels are permeable for small signalling
molecules (b1 kDa), like ATP, thereby playing an important role in
autocrine and paracrine purinergic signalling. Among all Panx
channels, Panx1 and Panx3 are closely related, while Panx2 is more
distant. Panx1 is ubiquitously expressed in many organs, including the
eye, thyroid, prostate, kidney and the liver, and a very high Panx1
expression has been found in the central nervous system (hippocam-
pus, neocortex, cerebellum, thalamus and hypothalamus), including
hippocampal and neocortical pyramidal neurons, interneurons, motor-
neurons and purkinje cells [79]. In contrast to the ubiquitously
expressed Panx1, Panx2 seems to be mainly expressed in the central
nervous system [80,81]. Finally, Panx3 is localized in the skin,
osteoblasts and chondrocytes [13,82,83]. Importantly, Panx-expression
levels seem to be dynamically regulated by physiological and
pathophysiological processes. For instance, although Panx2 is absent
in healthy astrocytes, ischemia/reperfusion induces the expression of
Panx2 in astrocytes [84]. According to altered mRNA and protein levels
upon epileptic or seizure activity [85–91], expression of Panx1 and
Panx2 is also shown to be increased as a result of seizure-like activity
[92].
Panx1 has been shown to interact with Panx2 and to a lesser
extent with Panx3 in a glycosylation-dependent manner [93]. Panx2
strongly interacts with the core and high-mannose species of Panx1,
but not with Panx3. All three Panx members are able to traffic to the
cell plasma membrane surface and to form functional hemichannels
[93]. Efficient plasmamembrane targeting of Panx1 channels seems to
require glycosylation at N254 [17,77,94]. The delivery of Panxs to the
cell surface, their dynamic organization at specific cell-surface
microdomains, and their dependency on an intact cytoskeletal
network, are beginning to emerge. Notably, all Panx isoforms are
not only present in cell-surface clusters, but also displayed intracel-
lular profiles [17,93]. In contrast to the well-studied connexin species
Cx43, whose complex network of direct and indirect binding partners
that control Cx43-life cycle has been extensively characterized, the
identification of the different Panx-binding partners is yet still in its
infancy. However, recent reports indicated the association of Panx1
with a protein subunit of the voltage-dependent potassium channel
[95], with P2X7 [96,97], and with actin microfilaments, regulating its
cell-surface localization and mobility [94] (Fig. 2). Actin directly binds
to the C-terminus of Panx1. The interaction of Panx1 and Panx3 with
actin microfilaments as well as functional cytoskeletal microfilaments
is required for proper Panx1 delivery and dynamics at the cell plasma
membrane surface. Importantly, these cytoskeletal interactions seem
to stabilize the cell-surface population of Panx1 and Panx3 isoforms
[94].
In earlier experiments, Panx1was found to enable the formation of
Ca2+-permeable gap junction channels between adjacent cells,
allowing direct intercellular Ca2+ diffusion and facilitating intercel-
lular Ca2+ wave propagation [13,98–101]. Recently, the link between
Panx channels and gap junction channels has been abandoned
[72,75,77,102]. Indeed, there were only few reports about Panxs gap
junction formation and all reported cases have been in overexpression
systems [13,103]. The glycosylation of Panx channels at asparagine
residues present at the extracellular site make functional docking of
two Panx hemichannels into a intercellular gap junction very unlikely
[17,76,77,102]. In addition, Panx channels lack a third extracellular
cysteine in the extracellular loops [14,82,104]. Therefore, it is
anticipated that unapposed Panx channels have very low affinity for
each other, also decreasing the effectiveness of Panx gap junctional
channel formation. Several hypotheses were raised to explain the gap
junction formation in some rare studies, such as the weakening of the
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glycosylation [75], the forced overexpression in oocyte systems and
the mixing up of Panx gap junction channels with connexin gap
junction channels [105]. Panx expression could indeed influence
expression of other proteins, e.g., the connexin expression and hence
influence the formation of connexin gap junction channel [105]. Yet,
the presence of pannexin gap junctional channels under normal
physiological conditions has not been demonstrated, andmost studies
actually support the assumption that Panxs, in particular Panx1, form
single membrane channels [16,17,73,77,82,96,106].
The opening of unapposed pannexin channels in the membrane is
triggered by a plethora of physiological triggers, including intracellular
Ca2+ release, membrane depolarization in the physiological range
(−20 mV to +20mV), mechanical stimulation and P2Xn receptor
activation, allowing the release of low-molecular weight signalling
molecules, like ATP [13,70,107]. Using the oocyte-expression system, a
large unitary conductance of about 500 pSwas determined for the fully
open state [70]. Although it is tempting to speculate that only Panxs
participate in hemichannel-mediated ATP release under physiological
conditions, it is clear that also connexin hemichannels can be opened
during physiological signalling. For instance, [Ca2+]i increases in the
range of physiologically relevant Ca2+ signalling (between 300 nM and
1 μM Ca2+) lead to the opening of Cx32 and CX43 hemichannels
[108,109] and thereby can contribute to physiological purinergic
signalling [110]. Although it is clear that Panx-hemichannel activation
is unaffected by changes in [Ca2+]o [111], the regulation mechanism of
the opening and closure of Panx hemichannels by changes in [Ca2+]i is
not fully understood and might be cell-type dependent. While patch-
clamp experiments on Panx1 expressed in Xenopus oocytes revealed
that increasing [Ca2+]i above the resting levels (N100 nM) leads to
larger Panx1 currents [107], in mammalian cells it has been reported
that [Ca2+]i increases do not trigger Panx1-hemichannel openingorATP
release [112,109]. Additionally, an increase in [Ca2+]i is not absolutely
required for Panx1-hemichannel activation in hippocampal neurons,
since the activation of Panx1 channels through NMDARs was indepen-
dent of the increase in [Ca2+]i, demonstrated by Panx1-hemichannel
opening in the presence of intracellular Ca2+ buffers [113]. Irrespec-
tively of their activation mechanism, it is however likely that Panx1
hemichannels play an important role in mediating ATP release and
intercellular communication. Therefore, opening of Panx1 hemichan-
nels may not only mediate intercellular communication via paracrine
purinergic signalling, but also control intracellular Ca2+ dynamics by
providing a Ca2+-influx pathway independent of the recently identified
store-operated Ca2+-influx mechanisms controlled by Stim/Orai.
A role for calmodulin on Panx1 hemichannels can, however, not be
ruled out. Although calmodulin-binding sites were not yet identified
on Panx1 thus far, calmodulin is an important regulator of Cx50 [114]
and Cx32 [115] channel gating, and also interacts with other Cx
isoforms, including Cx43 [116].
Also, endogenous “brake” mechanisms that prevent excessive and
thus pathophysiological opening of Cx43 hemichannels have been
identified [117]. Indeed, the activation of the actin cytoskeleton imposes
a strong inhibitory action onCx43hemichannels, preventing its opening
during high [Ca2+]i increases (N1 μM) or physiological triggers [117–
119]. For instance, thrombin acts on corneal endothelial cells and
inhibits Cx43-hemichannel opening in response to mechanical stimu-
lation [118,119].
Panxs are not exclusively localized in the plasma membrane, since
Panx1 is also abundantly detected in intracellular organelles such as
ER and the Golgi apparatus (Fig. 1) [18,81,103,120]. Panx1 over-
expression in human prostate cancer epithelial LNCaP cells, showed
accumulation in both the plasma membrane and in the ER [18],
implying that post-translational modification and assembly of
pannexons share the same route as demonstrated for connexins
[121,122]. Recently, it was reported that both Panx1 and Panx3 are co-
translationally inserted into the ER and transported by a COPII (coat
protein II)-dependent mechanism to the Golgi apparatus, where they
are substrates for further glycosylation and editing (Fig. 1) [94]. Panx2
is more abundant in intracellular compartments, except when co-
expressed with Panx1, when its cell-surface distribution increases by
two-fold [93]. Heteromeric Panx1/Panx2 channels are characterized
by compromised channel function, whereas Panx1/Panx3 channels
are normal functional channels. Apparently the functional state and
cellular distribution of Panxs is regulated by their glycosylation status
and interactions among Panx members [93].
4. Signalling by Panx channels located at the plasma membrane
4.1. Physiological signalling
Panx hemichannels can form channels with a large pore, which can
conduct molecules smaller than ~1 kDa [73], indicating that Panx
channels could be permeable to ions, second messengers and
neurotransmitters, such as ATP, IP3 and amino acids. In ectopic
expression systems, and also in normal physiological cell systems, like
taste bud receptor cell erythrocytes and in cultured astrocytes, Panx1
directly mediates release of ATP [73,75,78].
The Panx-mediated release of ATP in the extracellular environment
can serve as a physiological signal for intercellular communication as
well as a noxious signal that promotes cell death. Panx1-mediated ATP
release can activate P2Y receptors [107], thereby leading toATP-induced
ATP release. In contrast, ATP can also inhibit the opening of Panx1
channels [123]. This negative feedback of ATP on pannexin channels is
Fig. 2.Different Panx-binding partners and their localization in the cell. Panx1 interacts with a protein subunit of the voltage-dependent potassium channel. A regulatory cross-talk of
Panx1 with P2X7 is indicated and interaction of Panx1 with F-actin microfilaments at the carboxyl terminus is shown to regulate its cell-surface localization and mobility. Possible
binding partners of Panx1 in the ER are still to be elucidated, but may involve Panx2. In different studies, Panx2 has been observed in intracellular vesicle-like compartments in the
perinuclear region.
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important to prevent a deadly ATP-induced ATP release loop under
physiological signallingconditions thatwould inevitably lead to collapse
of energy gradients and cell death. The inhibition of Panx channels by its
permeant may provide an important brake on detrimental, excessive
Panx-channel opening [124]. In contrast to Cx32 and Cx43, the
regulation of Panx-channel activity by intracellular [Ca2+]i does not
display a bell-shaped dependence [108,109,117]. Therefore, the
inhibitory mechanisms that turn off channel activity will likely differ
between Panx and Cx hemichannels, involving an inhibitory effect of
ATP on Panx and Ca2+-dependent inhibition of Cxs through the
activation of the actin cytoskeleton-mediated contractility, respectively
[108,109,117].
Panx-hemichannel activity has been implicated in different
cellular and physiological systems as will be outlined below (Table 1).
4.1.1. Taste bud receptor cells
Aprototypical example of physiological Panx1-controlled purinergic
signalling occurs in the peripheral taste organ [120,125,126], where the
afferent output of gustatory receptor cells exclusively relies on the
extracellular release of ATP via a non-vesicular mechanism through
Panx1 hemichannels [127]. The binding of sapidmolecules to G-protein
coupled gustatory receptors in the taste bud receptor (Type II) cells
leads to activation of PLCβ2 and IP3-mediated Ca2+ release from
intracellular stores. This increase in [Ca2+]i is the trigger for activation of
the TRPM5 channel in the plasma membrane [128]. The opening of the
non-selective monovalent cation channel, TRPM5, results in Na+ influx
and membrane depolarization. Physiologically, tastant-evoked intra-
cellular Ca2+ release inducing TRPM5-mediated membrane depolar-
ization functions as a trigger for Panx-1-hemichannel opening and ATP
release, conveying downstream purinergic ATP-signalling events [128].
On the one hand, ATP will activate the ionotropic P2X2/P2X3 receptors
located on the post-synaptic gustatory nerve fibers of the facial and
glossopharyngal nerves [127]. On the other hand, ATP will also act on
P2X-receptors located on the adjacent pre-synaptic serotonergic
nerve (Type III) cells, which will result in the release of serotonin at
the pre-synaptic membrane of these cells [129,130]. Serotonin will
activate 5-HT3 receptors on the post-synaptic gustatory nervefiber cells,
thereby modulating the transmission of taste information from taste
buds to gustatory nerves [127]. In addition, multiple forms of feedback
exist: i) serotonin exerts negative feedback through 5-HT1A receptors
located on the receptor cell (Type II); ii) ATP and its degradation
product, ADP, exert positive feedback on the receptor cells through P2Y1
receptors located on the receptor cell to mediate autocrine excitation
(Type II) [131].
It is proposed that the frequency of action potentials in the taste
cell and the subsequent delivery of ATP in the extracellular
environment are proportional to the stimulus intensity, providing a
graded taste response. Importantly, ecto-ATPases are abundantly
present in the taste buds, allowing rapid and efficient degradation of
ATP [132,133]. Therefore, the presence of ATP-release mechanisms,
specific ATP receptors and ATP-clearance mechanisms support the
role of ATP as a key neurotransmitter linking taste buds and gustatory
nerve fibers. Recently, the essential contribution of Panx1 in this
cascade was confirmed in intact taste buds [74], supporting a clear
physiological role for Panx1-mediated ATP release in the cell-to-cell
communication between the taste bud receptor cells and the pre-
synaptic cells.
4.1.2. Hippocampus
Since physiological signalling processes can be controlled by
Panx1-mediated ATP release, it raises the question whether Panx,
which are highly expressed in a variety of neural cells, contribute to
ATP release from neurons during physiological brain activity. In this
way, Panx channels could mediate non-synaptic chemical coupling
and affect synaptic signalling [75]. Besides this chemical coupling, a
recent study showed that pyramidal neurons also display a direct
electrical coupling [134,135]. However, it remains elusive whether
these direct couplings involve pannexin channels. In any case,
hemichannels seem to play a role in the release of glutamate from
astrocytes [136]. However, the question whether this glutamate
release is mediated by Panx remains to be answered. Two recent
studies proposed the contribution of Cx43 [137] and/or volume-
sensitive channels [138]. Besides signalling processes, an important
function of gap junctional-protein family members seem to lie in the
coupling of neuronal networks, including astroglial networks, for the
exchange of metabolites [139].
4.1.3. Red blood cells
In erythrocytes, which contain high levels of Panx1, electrophys-
iological and dye-uptake experiments indicated the physiological
Panx-hemichannel opening upon depolarization, low oxygen expo-
sure and mechanical stimulation applied as a pressure [107]. Local
hypoxic conditions and red blood cell deformation are physiological
stimuli for ATP release by erythrocytes, which can trigger ATP-
induced ATP release via P2Y receptors located in the erythrocytes as
well as in the endothelial layer. It is proposed that intercellular Ca2+-
wave propagation, fuelled by ATP-induced ATP release and the
involvement of direct gap junctional channels, can lead to the release
of NO onto the vascular smooth muscle cell layer, causing its
relaxation and leading to vasodilation and increased local blood
circulation and oxygen delivery. These effects on the microcirculation
would involve an ATP-induced ATP release-signalling wave spreading
through the endothelial layer. This is likely to be mediated by the
concerted action of Panxs and P2Y receptors [107], given the highest
expression level of Panxs in the vasculature of the heart and skeletal
muscles. The vascular response to ATP could be amplified by the se-
cretion of cis- and trans-epoxyeicosatrienoic acids (EET) from eryth-
rocytes [140]. EETs are essential components of key vasoregulatory
mechanisms and are candidate endothelium-derived hyperpolarizing
factors [141]. These vaso-active lipid mediators are metabolized from
arachidonic acid and released by ATP-dependent stimulation of
erythrocyte P2X7 receptors. The latter action requires functional
channels, like CFTR and Panx.
4.1.4. Skeletal muscle cells
Depolarization of skeletal muscle cells (either in vitro by electrical
stimulation or in vivo by opening of nicotinic acetylcholine receptors
at the neuromuscular junction) leads to activation of the dihydropyr-
idine receptor and opening of RyR SR Ca2+-release channels, resulting
in the contraction of the skeletal muscle. A very recent report shows
that ATP is released during physical activity of skeletal muscle cells by
a mechanism involving Panx1 hemichannels, which have been
proposed to be present in T-tubules of adult skeletal muscle [142].
Extracellularly released ATP activates local, plasma membrane-
localized nucleotide receptors: P2X receptors that form ion channels
and P2Y receptors that are G-protein coupled receptors. Activation of
these receptors provoke a transient increase in [Ca2+]i with specific
kinetic properties. ATP-induced activation of P2X receptors leads to
an early, fast increase in [Ca2+]i, which is linked to excitation–
contraction coupling, whereas ATP-induced activation of P2Y recep-
tors leads to second, slow andmore gradual increase in [Ca2+]i, which
is linked to excitation–transcription regulation [143]. Although the
fast Ca2+ transients obtained by tetanic stimulation mainly are
mediated through DHPR-mediated RyR activation, it is clear that ATP
modulates the amplitude of these Ca2+ signals. Indeed, apyrase
reduced the depolarization-evoked Ca2+ transient by about 20%. It is
speculated that ATP-induced opening of P2X receptors may contrib-
ute to supplement the skeletal muscle cells with Ca2+ needed to
maintain contractions. In contrast, the second and slow increase in
[Ca2+]i was completely dependent on purinergic signalling, as apyrase
completely abolished the slow Ca2+ transient in response to tetanic
depolarizations. Although the role of ATP release for skeletal muscle
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physiology urges further exploration, it is clear that extracellular ATP
and its receptor targets may play an important role in muscle activity
and plasticity. Indeed, prolonged incubations with high [ATP]
(500 mM), caused up-regulation of IL-6 and c-fos at the mRNA level
[142]. Furthermore, a number of skeletal muscle pathologies have
been associated with alterations in extracellular ATP metabolism,
sensitivity towards ATP and expression of purinergic receptors
[144–147].
4.1.5. Airway epithelial cells
Recently, Panx1 channels have been implicated in the release of
ATP from airway epithelial cells in response to hypotonic shock. The
physiological role of ATP in this system seems to lie in the control
of mucociliary clearance, an important host defense mechanism
governed by the airway epithelium [148,149]. The mucociliary
clearance is dependent on adequate airway surface liquid volume
and the frequency of ciliary beating, both regulated by the release of
extracellular ATP. Mucociliary clearance is compromised when
paracrine ATP signalling and compensatory cAMP signalling are
inhibited [150,151]. Furthermore, using small-volume measurements
and cell-attached luciferase assays, extracellular [ATP] near the cell
surface was estimated to increase above 1 μM [152], a threshold
concentration of ATP believed to be needed for the activation of
endogenous P2Y receptors. Importantly, given the observation that
Panx1 contributes to about 60% of the total ATP that is released upon
hypotonic treatment, it is likely that compromised Panx1 function
would bring this concentration below the threshold for P2Y-receptor
activation. Hence, it is anticipated that Panx1 plays a crucial role in
maintaining proper airway epithelium function during stress
conditions.
4.1.6. Chondrocytes
Another physiological role for Panxs seems the regulation of
differentiation processes in a variety of cell types. Recently, Panxs
have been shown to function in the cartilage, which contain
specialized cells, chondrocytes [153]. These cells are not vascularized
and depend on diffusion and local signalling processes for their
oxygen/energy supply and physiological responses. Pannexin 3 is
highly expressed in chondrocytes and regulates chondrocyte differ-
entiation and proliferation. Panx3 attenuated proliferative responses
to parathyroid hormone and switched chondrocyte cell fate from
proliferation to differentiation. The underlying mechanism involves
Panx3-mediated increases in ATP mobilization and decreases in
intracellular cAMP levels and downstream cAMP-signalling events.
4.1.7. Keratinocytes
Panx not only regulates the differentiation of chondrocytes, but
also modulates the differentiation of keratinocytes [154]. In this case,
Panx1 and Panx3 display different roles. In rat epidermal keratino-
cytes, Panx1 overexpression resulted in a disturbed keratinocyte
differentiation and disorganized architecture of the organotypic
epidermis, whereas Panx-3 overexpression supported keratinocyte
differentiation. However, it remains to be elucidated how the channel
function of Panx and related ATP release regulates the differentiation
process in these cells.
4.1.8. Cells of the immune system
Purinergic ATP signalling acts as a paracrine messenger in the
immune system. A variety of immune cells, including macrophages
and T cells, express Panx channels. Importantly, recent studies
implicated the release of ATP upon T-cell receptor activation through
Panx1 hemichannels. Besides the well-known role of ATP as a “danger
signal” in the recruitment of the inflammasome (as will be discussed
later), there is growing evidence that ATP plays an important role in
the activation of regulatory T cells in vivo [155]. Effective activation of
T cells by T-cell receptor activation requires the release of ATP by
Panx1 hemichannels. The extracellular ATP exerts an autocrine action
through the activation of P2X7 receptors and downstream signalling
events involving MAPK activation [156]. These local ATP signals may
be provided by the opening of Panx1 hemichannels responsible for
autocrine signalling processes. Besides these processes, ATP may also
induce differentiation of T-helper cells [157], while its degradation
product adenosine, may play a role in the suppression of T-cell
apoptosis via A2A-receptor activation [158]. Yet, the contribution of
Panx1 hemichannels in the latter process has not been elucidated. In
summary, the release of extracellular ATP in immune responses is
likely to modulate the global functioning of the immune system,
including the activation, proliferation, differentiation, maturation and
apoptosis of immunologic cells.
4.2. Pathophysiological signalling
Aberrant or prolonged Panx-channel opening would lead to a
prolonged inward current, membrane permeabilization and the
collapse of ionic, metabolic and bio-energetic gradients.
4.2.1. Epileptiform-like activity in the hippocampus
It has been previously reported that oxygen and glucose deprivation
(OGD) lead to neuronal necrosis associated with a collapse of ionic,
energy and metabolic gradients [159,160]. OGD provoked opening
of large-conductance channels, with the electrophysiological and
pharmacological characteristics of Panx hemichannels [161]. Their
opening during OGD, even at the neural resting membrane potential,
is proposed to contribute to “anoxic depolarizations”, a key component
of ischemic cell death. The cellular loss of glucose andATP via these open
Panx hemichannels will further impair the recovery of the neuron from
the insult. Moreover, aberrant Panx-channel opening has also been
observed in pyramidal neurons, where N-methyl-D-aspartate receptor
(NMDAR)activation leads toa secondary, prolonged inward current and
dyeflux thatwere abolishedbyusing specific Panx1-inhibitory peptides
and siRNA against Panx1 [162]. Therefore, it is proposed that Panx1-
hemichannel opening during increased endogenous NMDAR activity
can trigger epileptiform seizure activity in the hippocampus.
4.2.2. Fibrosis in cardiac myocytes
Besides neuropathophysiological conditions, uncontrolled Panx1-
hemichannel openinghas been implicated in cardiacfibrosis in response
to pressure overload. Upon mechanical stress, cardiac myocytes release
ATP and UDP via Panx1 hemichannels, leading to stimulation of
purinergic receptors and subsequent activation of guanine nucleotide-
binding proteins. As a result, induction of the expression of a number of
fibrogenic factors (like transforming growth factor-β and connective
tissue growth factor) occurs and leads to proliferation of cardiac
fibroblasts [163].
4.2.3. Inflammatory responses
High extracellular [ATP] originating from damaged or death cells or
prolonged Panx1-hemichannel opening may contribute to inflammatory
responses andare considered “danger signals” to the immune systemthat
will lead to cell death if sustained [97,164]. An excellent receiver for these
signals is the P2X7-receptor, since this type of P2-receptors requires very
high [ATP]e (N100 μM) for its activation and are not desensitized upon
stimulation with high [ATP]e (N100 μM). Furthermore, there is growing
evidence that Panx1plays a role in the immune system: i) Panx1 channels
directly interact with P2X7 receptors, and ii) stimulation of P2X7 by ATP
can lead to activation of caspase-1 and secretion of IL-1βwithin minutes
in a Panx-1-dependent pathway [97,165,166]. In cells of the innate
immune system (monocytes, macrophages), P2X7 stimulation results in
the formation of a non-selective large pore, likely to be the Panx-1
hemichannel itself [165,167]. It is clear that P2X7-mediated Panx-1
activation leads to the assembly of the NLRP3 (Nucleotide-binding
domain and leucine-rich repeat receptor containing pyrin domain)
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inflammasome complex [164,168,169]. However, it is still under debate
whether Panx-1 forms the direct release/entry pathway for signalling
molecules like ATP and IL-1β in this process, since Panx-1 shows many
characteristics of a chloride channel [112,166]. Currently, it is also
unknown what the exact molecular links are between the P2X7/Panx-1
complexand the inflammasome. It appears that thePanx-1 channel forms
a pore that allows activation of small pathogen-associated molecular
patterns (PAMPs) [169,170]. Recognition of PAMPs as endogenous
ligands by cytosolic NOD-like family receptors would enhance the
formation of the multimolecular inflammasome complex at which
activation of caspase-1 occurs. Interestingly, NLRP3 inflammasome
activation followed by IL-1β secretion has recently been found to enable
a link between innate (inflammatory) and acquired (cognate) immune
responses. IL-1β secretion from dendritic cells is found to be required for
T-cell priming [171]. Since this may find its application in anti-cancer
immunotherapies, it would be tempting to speculate that increased
Panx1 opening could enhance T-cell priming in vivo.
Besides the role of Panx1/P2X7 in the activation of the inflamma-
some in monocytes and macrophages, a recent study reported their
contribution to the rapid activation of the inflammasome in neurons
and astrocytes [172]. Although the role of K+ in the mechanism
underlying the activation of the inflammasome appears to be different
in both systems, it is clear that a similar coupling between Panx1 and
P2X7 signalling occurs in the neural system and underlies the rapid
cell death that occurs upon P2X7 activation by extracellular ATP.
Another example of the contribution of ATP in inflammatory
responses, is the accumulation of extracellular ATP triggering
the onset of lung asthmatic airway inflammation [173]. ATP promotes
T-helper2 cell sensitization by recruitment and activation of myeloid
dendritic cells that present the processed inhaled antigen. While the
source of the ATP is yet undefined, Panx-1 channels have been
implicated in ATP release from airway epithelial cells and are highly
expressed in alveolar macrophages [174].
Cigarette smoke, an inducer of lung emphysema and cause of
inflammatory chronic obstructive pulmonary disease (COPD), triggers
increased production and release of ATP by neutrophils [175]. While
the exact molecular mechanism is not yet clear, ATP releasewas found
not to be caused by cell death. P2-receptors seem to play an important
role in the pathogenesis, as smoke induces P2Y2-receptor up-
regulation, which is involved in neutrophil recruitment. Blocking of
P2-receptors inhibits the inflammation process [176]. Interestingly,
Panx-1 hemichannel inhibition is partially successful in preventing
Panx-1/P2X7-dependent neutrophil airway influx and cytokine
production in a mouse model for lung inflammation and pulmonary
fibrosis. These results suggest that ATP is released through the Panx-1
hemichannel after activation by P2X7 interaction [177]. However, it is
not unlikely that other hemichannels contribute to intracellular or
cell–cell signalling-cascades in the lung, since activated neutrophils
are shown to release ATP mainly via Cx43 [178].
5. Signalling by Panx channels located at the ER and other
intracellular compartments
Panxs are believed to preferentially reside in a hemichannel
configuration, which is important in paracrine signalling, and can
mediate transmembrane transport of Ca2+ and ATP in response to
physiological and pathological stimuli [17,77,102].
5.1. ER Ca2+-leak channels
In addition to the hemichannel and gap junction function, Panx1
channels were shown to form Ca2+-permeable channels in the ER [18]
(Fig. 3 and Table 2). Overexpression of Panx1 channels in prostate
cancer cells provoked a severe decrease in the amount of Ca2+ that
Fig. 3. Panx1 as an ER Ca2+-leak channel. Amodel for the regulation of [Ca2+]ER by ER-located Panx1 Ca2+-release channels. Under normal conditions, Panx1 levels may contribute to
the cellular rheostat, maintaining [Ca2+]ER within a physiological range (~600 uM). Under these conditions, normal IP3R-mediated Ca2+ signalling will occur in response to
extracellular signals and ER-stress sensors will be dormant. Panx1 down-regulation can lead to increased [Ca2+]ER, which will sensitize the ER towards intracellular IP3 levels. As a
result, excessive Ca2+ signals may arise upon agonist-induced Ca2+ signalling, leading to mitochondrial Ca2+ overload and cell death. In contrast, Panx1 up-regulation, which may
occur during pathophysiological conditions, can lead to a severe decrease in [Ca2+]ER. The latter has been associated with the activation of the ER-stress sensors and the activation of
pro-apoptotic unfolded protein responses. Interestingly, prostate cancer cells seem to exploit Panx1 channels by increasing their levels in the ER membrane. As a result, dampened
Ca2+ signals will arise in response to IP3R activation, resulting in an increased resistance towards mitochondrial Ca2+-overload-associated cell death. Hence, increasing Panx1 at the
ER may provide an escape route for cancer cells by preventing Ca2+-overload-mediated cell death. Nevertheless, under these conditions, an adaptive unfolded protein response may
occur, supporting their survival during decreased [Ca2+]ER. As a result, cancer cells may be particularly vulnerable towards chemotherapeutic agents that act as ER-stress inducers.
Table 2
Questions about ER-localized Panx channels.
Does Panx1 reside in the ER and affect the [Ca2+]ER of cells other than prostate
cancer cells, in particular of normal primary cells?
Do other ER-localized Panx isoforms affect [Ca2+]ER?
Are Panx channels constitutive passive leak channels or is their activity
dynamically regulated by intracellular signalling molecules?
Are conditions known to affect Panx levels or activity associated with changes in
[Ca2+]ER?
Do high endogenous levels of Panx1 channels, like observed in prostate cancer
cells, protect cells against pro-death signals?
Are prostate cancer cells addicted to these high levels of Panx1 channels?
Do other cancer cells elevate Panx1-channel levels in response to oncogenic
transformation?
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can be released from the ER upon SERCA inhibition by thapsigargin.
These results indicate that increasing Panx1 levels causes a decrease
in the steady-state intraluminal [Ca2+]ER [18]. This decrease in
[Ca2+]ER was not observed when Cx43 or Cx32 was overexpressed,
indicating that i) Panx1-mediated Ca2+ leak pathway is probably
not an artefact of accumulation of assembled channels in the ER,
and ii) the formation of Ca2+-permeable channels in the ER is not
a general property of gap junction/hemichannel-forming proteins.
Experiments in digitonin-permeabilized LNCaP cells allow a direct
assessment of the Ca2+-leak properties of the ER. In these
experiments, Panx1 overexpression provoked a dramatic increase
in the passive Ca2+-leak rate of the ER. Importantly, this increased
Panx1-mediated Ca2+-leak rate was not affected by inhibiting IP3R/RyR
activity. In addition, cells overexpressing Panx1 did not display an
increase in proteins previously proposed to affect the passive Ca2+ leak
from the ER, like the ratio of pro- and anti-apoptotic Bcl-2-family
members. The ER-bound Panx1 could be either a pool of unprocessed
precursor proteins [81,179] or assembled functional pannexons that
serve as ER Ca2+-release channels, thereby facilitating Ca2+-leak from
the ER [18]. One caveat of overexpressing Panx1 in prostate cancer cells,
which do contain high levels of endogenous Panx1, is the accumulation
and entrapment of the ectopic Panx1 channels in the ER, whereas
endogenous Panx1 channels may travel to the plasma membrane.
Hence, the fact that knock down of endogenous Panx1 channels by
siRNA approaches in human prostate cancer cells increased the Ca2+
content of the ER by decreasing the efflux rate of Ca2+ from the ER,
excludes this putative caveat. Moreover, functional and pharmacolog-
ical characterization of Panx1 channels by electrophysiological
approaches revealed that Panx1 channels mediate an outward current
that is inhibited by CBX and non-selective chloride channel/anion
transporter blockers [112]. Therefore, it is hard to conceive how Panx1
channels that resemble chloride/anion-permeable channels can func-
tion as Ca2+-leak channels and this requires further investigation.
Moreover, further research is required to assess whether Panx1
channels reside in the ER and affect ER Ca2+ homeostasis in cells other
than prostate cancer cells and thus function as bona fide Ca2+-leak
channels that account for a substantial amount of the passive Ca2+ leak
of the ER. In particular, the effect of Panx1 knock down in cells
endogenously expressing high levels of Panx1 on ER Ca2+ should be
examined. In addition, it would be exciting to unravel whether
the formation of ER Ca2+-leak channels is a general property of the
Panx-channel family, using Panx2 and Panx3-overexpressing systems
or -knock down approaches. Nevertheless, the finding that Panx1 is at
least able to form Ca2+-permeable channels is of utmost importance,
since the passive Ca2+ leak is one of the most enigmatic processes
involved in the regulation of ER Ca2+ levels from which its molecular
nature and mechanism is very poorly understood.
Moreover, it is not known whether Panx1 channels in the ER are
regulated by intracellular signalling molecules, by the ER–Ca2+
content or by [Ca2+]i. Since Panx1-hemichannel activity is unaffected
by changes in [Ca2+]o [111], it may be questioned whether [Ca2+]ER
affects Panx1 opening. On the other hand, small increases in [Ca2+]i
may stimulate the Ca2+ leak from the ER, as Panx-hemichannel
activity measured in patch-clamp experiments on Panx1-expressing
Xenopus oocytes is increased by increasing [Ca2+]i [107]. Neverthe-
less, the general role and regulation of Panx channels in the ER needs
to be examined in other cell systems.
Furthermore, it has not yet been documented whether pathophys-
iological conditions, known to increase either Panx1 activity or
expression level, like after oxygen and glucose deprivation of pyramidal
neurons of the cortex or hippocampus [74,162], affects the Ca2+ leak
from the ER and thus the steady-state [Ca2+]ER in a Panx1-dependent
manner.
Although the function and properties of Panx1 as a Ca2+-leak
channels needs to be scrutinized and characterized in other cellular
systems under a variety of physiological and pathophysiological
conditions, it is important to note that to date the molecular basis of
the passive Ca2+ leak from the ER generally has been poorly char-
acterized and is a matter of debate [180]. Despite a poor understand-
ing of the molecular mechanisms underlying the passive Ca2+ leak, a
tight control of the [Ca2+]ER is of utmost importance for physiological
Ca2+ signalling, cell survival and protein folding [180,181].
On the one hand, increases in Panx1-channel activity or -expression
levels may contribute to the development of diseases by decreasing
[Ca2+]ER below a critical level. Under those circumstances, ER-resident
Ca2+-dependent chaperones, like calreticulin,may function improperly,
leading to the accumulation of unfolded proteins and activation of the
Unfolded Protein Response [182,183]. Therefore, althoughnormal levels
of Panx1 in the ERmay contribute to a decrease of the [Ca2+]ER andmay
be protective against apoptosis, pathophysiological changes in the
Panx1 profile of cells (e.g. as a result of neuronal seizure) may lead to
activation of severe ER stress and cell death. Consequently, besides the
role of Panx1 in ATP-induced cell death as the “large pore” of the P2X7
receptor, changes inPanx1 levels in theERand its subsequentdisturbing
effects on ER Ca2+ homeostasis may contribute or promote apoptotic
cell death involving UPR.
On the other hand, cells lacking Panx1 channels in the ER may
display ER Ca2+ overload. Under these circumstances, the ER could
become hypersensitive towards agonist-induced Ca2+ signalling by
provoking excessive Ca2+ release upon IP3R activation. Prolonged or
exuberant Ca2+ signals will perturb mitochondrial function due to the
intimate ER/mitochondrial connections. As a result, excessive Ca2+
signals may lead to mitochondrial outer membrane permeabilization
and cell death. In particular, cells with increased ER Ca2+ levels will
become particularly sensitive towards pro-apoptotic triggers that
promote or synergize with excessive Ca2+ signalling. In this
perspective, the high levels of Panx1 in the prostate cancer cells
may be acting as a protective mechanism against their on-going pro-
apoptotic signalling triggered by their oncogenic phenotype by
lowering their [Ca2+]ER and thus rendering them more resistant
towards the on-going oncogenic signals that would be lethal in
normal cells. In this perspective, it would be important to investigate
whether prostate cancer cells are addicted to these elevated Panx
levels. Hence siRNA approaches targeting Panx1 in prostate cancer
cells may elucidate whether Panx1 depletion provokes cell death or
sensitizes towards apoptotic inducers. Moreover, the elevated Panx1
levels observed in prostate cancer cells and the subsequent lowering
of [Ca2+]ER may render these cells particularly vulnerable towards
anti-cancer therapies and drugs that provoke ER stress, like
xanthuhomol [184,185]. This approach has been shown to be
successful in other cancer malignancies, like chronic lymphocytic
leukemia, by provoking ER-stress-induced pro-apoptotic UPR due to
their on-going ER-stress signalling.
5.2. Tumor-suppressive inhibition of cell growth
In contrast to Panx1, which has been implicated in a variety of
physiological and pathophysiological conditions, the physiological
role of Panx2 remains largely undiscovered. Recent studies pointed
towards a role for Panx2 in gliomagenesis and oncogenicity [186].
Indeed, by performing a high-throughput cDNAmicroarray analysis of
human brain-tumor samples, Panx2 mRNA levels were found to be
reduced in C6 glioma cells in comparison with rat primary astrocytes
[83]. The decreased expression of Panx2 was confirmed at the protein
level in a variety of human glioma and glioblastoma cell lines [186].
Furthermore, human Panx2 is located within a chromosomal region
often affected in astrocytomas and ependymomas [187–190]. Impor-
tantly, stable Panx2-expressing C6 glioma cells displayed an altered,
flattened morphology, a reduction in cell proliferation rate through
suppression of the cell cycle and decreased saturation density,
indicating that Panx2 suppression suppresses the oncogenicity of
the C6 glioma cells [186]. These observations were confirmed by
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anchorage-independent growth assays and by tumorigenicity assays
in immunodeficient mice. Strikingly, these functions of Panx2 seemed
independent of its channel function and from its putative action at the
plasma membrane. Indeed, the expression pattern of Panx2 revealed
an intracellular, cytoplasmic localization with a prominent presence
at the perinuclear region in a vesicle-like pattern. In this respect, Lai et
al [186] proposed that the long C-terminal tail of Panx2 allows the
formation of intracellular protein–protein complexes to mediate its
function. Hence, the studies of Prevarskaya on Panx1 [18] and of Naus
on Panx2 [186] also implicate that Panx1 and Panx2 have distinct
cellular functions and implications for oncogenicity. While increasing
Panx1 levelsmight be a pro-survival strategy of certain types of cancer
cells, like prostate cancers, to escape cell death, decreasing Panx2
levels might be pro-proliferative strategy of other types of cancer
cells, like brain-related tumors as gliomas, to promote cell growth and
oncogenicity.
5.3. Neuronal differentiation
Very recently, Panx2 in the hippocampus has been implicated in
postnatal hippocampal neurogenesis [191]. The expression levels,
the cellular localization and post-translational modification through
S-linked palmitoylation of Panx2 channels are dynamically regulated
during the hippocampal neurogenic and differentiation program:
first, multipotent neural progenitor cells expresses S-palmitoylated
Panx2 that is located in the ER and the Golgi apparatus; later in the
program, Panx2 disappears during intermediate progeny, but Panx2 is
re-expressed following terminal neuronal differentiation of matura-
tion. Importantly in mature hippocampal granule neurons, Panx2 is
present in the plasma membrane, where it forms rod-like structures.
Similar observations were made in N2a cells: undifferentiated N2a
cells express Panx2 in intracellular compartments, whereas differen-
tiation of N2a leads to relocalization of Panx2 to the plasma
membrane. Importantly, knockdown of Panx2 in N2a cells promotes
neuronal differentiation. Hence, it was proposed that intracellularly
located, S-palmitoylated Panx2 channels play a modulatory role in
neurogenesis. Intracellular Panx2 might be important to maintain
stem-cell properties of the neural progenitor cells or regulate the
timing of their transition into differentiated andmature neurons upon
neurogenic stimulation. The exact role of Panx2 at the ER must be
elucidated, but a potential interaction between S-palmitoylated Panx2
with Panx1 might contribute to the ER-targeting of Panx1 in neural
progenitor cells and to the functional properties of Panx1 channels in
the ER.
6. Conclusions
It is clear that Panx fulfill a crucial function as undocked hemichannels,
providing a conduit for physiologically relevant signallingmolecules, such
asATP. TheconcertedactionofPanx togetherwithP2YandP2Xn receptors
allows a very complex regulation of autocrine and paracrine signalling
processes. These seem of relevance in signal-transduction cascades in
sensory responses, like in the taste bud receptor cells, in red blood cells to
regulate of the microcirculation in the micro-vascular system and in
inflammatory responses involving the engagement of P2X7-death
receptor complexes. By contrast, aberrant opening of Panx channels
seem detrimental in the brain. An ATP-induced inhibition of ATP release
by Panx channels therefore provides a possible negative feedback loop,
preventing this excessive opening. Notably, novel roles for Panx channels
have emerged during the last year. These roles may be Panx-isoform
specific and do not necessarily take place at the cell plasma membrane,
but may involve other cellular organelles, like the ER and the perinuclear
region. In this respect, the role of Panx1channels as aCa2+-leak channel to
regulate ER Ca2+ homeostasis is intriguing. Since the ER plays a central
role in the control of intracellular Ca2+ signals and protein folding,
changes in Panx expression and activity might lead to disturbed ER Ca2+
homeostasis, which is a central paradigm in many pathophysiological
conditions. Furthermore, other Panx isoforms, like Panx2, might exert
important functions at intracellular compartments in the proliferation of
brain-tumor cells and differentiation of neural progenitor cells. Therefore,
the role of Panx-channel complexes in intracellular compartments during
physiological signalling, including the modulation of Ca2+-signalling
dynamics and processes, and in response to pathophysiological condi-
tions, including excitotoxicity in neural cells and ischemia, requires
further investigations.
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